enterovirus
eg
polioviru
coxsackieviru
rhinoviru
includ
mani
human
pathogen
caus
variou
mild
sever
diseas
especi
young
children
unfortun
antivir
drug
treat
enteroviru
infect
approv
yet
past
decad
sever
directact
inhibitor
develop
includ
capsid
binder
block
viru
entri
inhibitor
viral
enzym
requir
genom
replic
capsid
binder
proteas
inhibitor
clinic
evalu
fail
due
limit
efficaci
toxic
issu
altern
approach
hosttarget
inhibitor
potenti
broadspectrum
activ
identifi
furthermor
drug
repurpos
screen
recent
uncov
promis
new
inhibitor
dispar
viral
host
target
togeth
find
rais
hope
develop
broadrang
antienterovir
drug
picornavirida
constitut
larg
famili
nonenvelop
positivestrand
rna
rna
virus
current
consist
genera
genu
enteroviru
far
largest
genu
compris
mani
human
pathogen
includ
polioviru
coxsacki
b
virus
echovirus
number
enterovirus
eg
rhinovirus
infect
nonpolio
enterovirus
result
wide
varieti
symptom
includ
handfootandmouth
diseas
conjunct
asept
mening
sever
neonat
sepsislik
diseas
acut
flaccid
paralysi
wherea
infect
rhinovirus
caus
common
cold
well
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
review
ref
vaccin
avail
polioviru
develop
vaccin
enterovirus
seem
unfeas
given
larg
number
sero
type
ie
nonpolio
enterovirus
rhinovirus
henc
great
need
broadact
antivir
enterovirus
review
recent
effort
develop
directact
antivir
well
host
factortarget
inhibitor
treat
enteroviru
infect
tabl
enteroviru
capsid
icosahedr
pseudo
structur
compos
copi
four
capsid
protein
enteroviru
replic
cycl
figur
initi
bind
virion
receptor
enteroviru
receptor
protein
receptor
belong
ig
superfamili
integrin
receptor
famili
review
ref
receptor
usual
bind
canyon
depress
virion
surfac
around
fivefold
axe
symmetri
receptorbind
induc
virion
destabil
releas
pocket
factor
fatti
acid
locat
hydrophob
pocket
beneath
canyon
initi
virion
uncoat
socal
capsid
binder
extens
studi
class
antienterovir
compound
compound
replac
pocket
factor
canyon
therebi
block
virion
uncoat
clinic
trial
capsid
binder
pleconaril
vapendavir
aka
pocapavir
aka
current
progress
recent
complet
statu
describ
last
year
sinc
anoth
trial
pleconaril
conduct
treatment
neonat
enteroviru
sepsi
show
greater
surviv
among
pleconaril
recipi
major
drawback
capsid
binder
rapid
emerg
resist
inde
clinic
trial
treatment
rhinoviru
infect
pleconaril
compoundresist
virus
isol
addit
natur
occur
pleconarilresist
virus
eg
echoviru
strain
report
resist
issu
may
complic
applic
capsid
binder
clinic
enteroviru
life
cycl
begin
attach
viru
particl
cellular
receptor
follow
intern
particl
host
cell
genom
releas
directli
mani
capsid
binder
activ
rhinoviru
b
speci
member
member
rhinoviru
c
speci
recent
elucid
atom
virion
structur
cryoem
reveal
uniqu
spiki
structur
vastli
differ
enteroviru
speci
furthermor
hydrophob
pocket
fill
bulki
hydrophob
residu
therebi
provid
suffici
space
pocket
factor
capsid
binder
featur
like
explain
rhinoviru
c
speci
respons
pocketbind
compound
atom
structur
rhinovirusc
also
reveal
potenti
bind
site
sialic
acid
sequenceconserv
surfac
depress
sialic
acid
recent
shown
also
facilit
entri
target
sialic
acid
review
ref
also
appli
influenza
viru
could
approach
inhibit
rhinovirusc
infect
one
bestdescrib
compound
target
sialic
acid
bacteri
sialidas
cleav
acid
linkag
test
phase
ii
clinic
trial
para
influenza
infect
also
inhibit
replic
vitro
remain
test
vivo
kb
rna
genom
enterovirus
encod
singl
polyprotein
harbor
structur
protein
nonstructur
protein
figur
polyprotein
proteolyt
process
individu
protein
viral
proteas
pro
pro
pro
develop
proteas
inhibitor
focus
particularli
pro
sinc
conserv
pro
one
potent
pro
inhibitor
develop
year
rupintrivir
aka
rupintrivir
peptidomimet
compound
irrevers
bind
catalyt
site
pro
activ
broad
panel
enterovirus
compound
select
clinic
trial
despit
poor
oral
bioavail
although
result
rhinoviru
challeng
trial
promis
rupintrivir
reduc
diseas
sever
natur
infect
patient
henc
clinic
develop
halt
howev
mani
rupintrivir
deriv
current
develop
furthermor
nonpeptidomimet
small
molecul
inhibitor
develop
circumv
difficulti
bioavail
yet
evalu
clinic
trial
viral
rnadepend
rna
polymeras
pol
catalyz
viral
rna
synthesi
replic
complex
associ
socal
replic
organel
ro
see
inhibitor
pol
divid
two
class
base
structur
nucleosidenucleotid
inhibitor
ni
nonnucleosidenucleotid
inhibitor
nni
antivir
ni
act
two
way
incorpor
viral
genom
mimick
nucleotid
induc
lethal
mutagenesi
termin
elong
nascent
chain
inhibit
viral
replic
indirect
manner
affect
cellular
nucleotid
pool
review
ref
ni
enterovirus
develop
compound
develop
virus
offer
promis
result
ribavirin
clinic
use
treatment
hepat
c
viru
hcv
infect
anoth
exampl
fail
preclin
studi
treatment
dengu
viru
infect
due
toxic
howev
lower
concentr
protect
mice
lethal
challeng
without
show
cytotox
drug
repurpos
concept
use
compound
develop
certain
diseas
treat
differ
condit
offer
attract
altern
de
novo
drug
develop
profound
pharmacolog
toxicolog
profil
alreadi
avail
allow
bypass
expens
pre
clinic
studi
exampl
ni
gemcitabin
anticanc
drug
recent
found
exert
broadspectrum
antienterovir
activ
besid
incorpor
nascent
viral
rna
gemcitabin
suggest
block
access
nucleotid
activ
side
polymeras
furthermor
gemcitabin
block
viral
genom
replic
inhibit
ribonucleotid
reductas
cellular
enzym
catalyz
convers
deoxyribonucleotid
ribonucleotid
dose
gemcitabin
need
antivir
activ
significantli
lower
dose
anticanc
activ
rais
hope
applic
without
toxic
effect
inher
mani
anticanc
drug
directact
antivir
hosttarget
strategi
combat
enteroviru
infect
bauer
et
al
figur
legend
continu
translat
polyprotein
process
viral
encod
proteas
individu
viral
protein
nonstructur
protein
rewir
host
cell
membran
gener
replic
organel
ro
viral
rna
replic
sever
host
protein
phosphatidylinositol
iii
beta
osbp
oxysterolbind
protein
recruit
ro
viral
protein
result
ro
uniqu
lipid
composit
genom
replic
start
synthesi
complementari
negativestrand
rna
use
templat
synthesi
larg
number
rna
molecul
newli
synthes
rna
either
enter
new
round
genom
replic
packag
capsid
protein
build
infecti
particl
virus
releas
nonlyt
mechan
well
upon
cell
lysi
inhibitor
differ
stage
replic
cycl
depict
red
sever
nni
pol
identifi
eg
gliotoxin
aurincarboxil
acid
mechan
action
poorli
understood
except
amilorid
decreas
polymeras
fidel
review
ref
identifi
novel
broadrang
enteroviru
inhibitor
target
rna
templateprim
site
core
pol
make
first
antienterovir
compound
mechan
action
unfortun
efficaci
anim
model
remain
test
due
problem
formul
compound
vivo
use
altern
strategi
pol
inhibit
although
thu
far
unexplor
may
interfer
posttransl
modif
pol
like
sumoyl
ubiquitin
import
pol
activ
highli
conserv
viral
protein
atpas
attract
target
broadspectrum
enteroviru
inhibitor
atpas
sever
function
genom
replic
review
ref
sever
structur
dispar
atpas
inhibitor
identifi
guanidin
hydrochlorid
hbb
addit
drug
repurpos
screen
recent
uncov
number
fdaapprov
drug
fluoxetin
pirlindol
dibucain
zuclopenthixol
inhibit
replic
enteroviru
speci
b
member
sinc
mutat
atpas
provid
resist
compound
consid
target
atpas
inde
fluoxetin
ie
prozac
shown
interfer
atpas
activ
atpas
mechan
inhibit
drug
yet
unravel
recent
vitro
experi
confirm
longpresum
atpdepend
rna
helicas
activ
atpaseindepend
rna
chaperon
function
atpas
pave
way
studi
elucid
mechan
action
atpas
inhibitor
detail
far
atpas
inhibitor
test
clinic
trial
howev
fluoxetin
effect
immunocompromis
child
chronic
enteroviru
enceph
impli
atpas
inhibitor
potenti
clinic
use
virion
morphogenesi
poorli
understood
stepwis
process
first
step
liber
polyprotein
assist
chaperon
heat
shock
protein
process
ie
precursor
spontan
form
protom
five
protom
subsequ
assembl
pentam
twelv
turn
form
empti
capsid
aka
procapsid
assembl
pentam
procapsid
support
glutathion
yet
unidentifi
mechan
govern
interact
atpas
activ
replic
viral
rna
includ
procapsid
form
provirion
final
step
virion
morphogenesi
cleavag
form
stabl
icosahedr
particl
assembl
inhibitor
identifi
far
geldanamycin
analog
target
inhibit
process
buthionin
sulfoximin
inhibitor
glutathion
synthesi
small
molecul
coval
bind
glutathion
imped
role
glutathion
morphogenesi
yet
enterovirus
reli
glutathion
therebi
preclud
glutathion
import
target
broadspectrum
inhibitor
virus
critic
depend
specif
host
factor
recent
year
sever
host
factor
requir
enteroviru
antivir
strategi
tabl
overview
directact
hosttarget
inhibitor
discuss
review
capsid
binder
pirodavir
pleconaril
b
pocapavir
b
vapendavir
b
pro
inhibitor
peptid
mimet
rupintrivir
b
analog
eg
compound
nonpeptid
mimet
pol
inhibitor
nucleosidenucleotid
analog
gemcitabin
ribavirin
nonnucleosidenucleotid
analog
amilorid
aurintricarboxil
acid
gliotoxin
buthionin
sulfoximin
bso
replic
discov
spur
hostdirect
drug
develop
sinc
host
factor
appear
use
mani
even
enterovirus
inhibitor
cellular
factor
may
broadspectrum
activ
enterovirus
like
rna
virus
induc
specif
alter
intracellular
membran
lipid
homeostasi
form
replic
organel
ro
format
enteroviru
ro
mediat
concert
action
viral
protein
well
select
set
hijack
host
factor
recent
review
ref
one
pivot
host
factor
phosphatidylinositol
type
iiib
recruit
membran
viral
protein
enrich
ro
phosphatidylinositol
lipid
essenti
genom
rna
replic
essenti
enterovirus
inhibitor
enzym
eg
review
ref
broadspectrum
activ
howev
inhibitor
show
lethal
toxic
mice
affect
lymphocyt
function
vitro
stall
develop
inhibitor
besid
fact
inhibitor
may
toxic
activ
may
also
overcom
mutat
viral
recent
publish
itraconazol
clinic
use
antifung
drug
also
anticanc
properti
identifi
drug
repurpos
screen
broadspectrum
enteroviru
inhibitor
identifi
oxysterolbind
protein
osbp
novel
target
itraconazol
respons
antivir
effect
osbp
protein
shuttl
cholesterol
ergolgi
membran
contact
site
osbp
recruit
ro
increas
lipid
shuttl
activ
essenti
viral
genom
replic
osbp
inhibitor
eg
natur
compound
also
impair
enteroviru
replic
rhinoviru
mous
model
prophylact
intranas
treatment
itraconazol
reduc
viral
titer
patholog
rais
expect
topic
appli
itraconazol
prevent
treat
common
cold
cyclophilin
play
role
uncoat
process
line
cyclophilin
inhibitor
cyclosporin
block
replic
cyclophilin
facilit
protein
fold
catalyz
peptid
bond
isomer
also
play
role
replic
rna
virus
includ
hcv
coronavirus
review
ref
capsid
binder
current
advanc
clinic
trial
inher
problem
rapid
resist
develop
rais
concern
develop
proteas
inhibitor
requir
synthesi
rel
complex
peptidomimet
molecul
atpas
pol
may
promis
target
directact
antivir
drug
inhibit
small
molecul
sever
inhibitor
factor
found
broadrang
antienterovir
activ
target
broadspectrum
antivir
drug
host
factor
mani
host
factor
share
enterovirus
possibl
downsid
chanc
advers
effect
toxic
exemplifi
inhibitor
late
sever
enteroviru
inhibitor
discov
drug
repurpos
screen
compound
alreadi
avail
least
quit
advanc
pre
clinic
develop
respect
condit
thu
shorten
develop
process
importantli
sever
inhibitor
broadrang
sometim
even
panenteroviru
activ
besid
target
individu
viral
cellular
protein
emerg
concept
drug
design
interfer
essenti
proteinprotein
interact
case
enteroviru
infect
one
may
pharmaceut
disrupt
essenti
interact
viral
protein
host
factor
like
hamper
viru
replic
without
caus
overt
toxic
issu
may
associ
inhibit
host
protein
unfortun
proteinprotein
interact
address
current
drug
format
includ
small
molecul
recent
develop
small
cellperm
synthet
protein
scaffold
eg
alphabodi
may
potenti
lead
novel
approach
target
proteinprotein
interact
entero
virusinfect
cell
sinc
target
drug
discoveri
depend
heavili
basic
knowledg
viru
replic
fundament
research
role
viral
enzym
well
essenti
host
factor
enteroviru
replic
remain
need
develop
broadrang
antivir
drug
import
pathogen
